Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oseltamivir Clear all
Completed Phase 3 Interventional Results available

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

NCT00545532
View directory record Official record
Conditions
Influenza, Human
Interventions
oseltamivir, placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
60
States / cities
Birmingham, Alabama • Beverly Hills, California • Burbank, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers

NCT04536415
View directory record Official record
Conditions
Bioequivalence
Interventions
Oseltamivir Phosphate 75 mg capsules, Tamiflu capsules 75 mg
Drug
Lead sponsor
Austarpharma, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 28, 2026, 9:38 PM EDT
Terminated Phase 4 Interventional Results available

A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

NCT01032837
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
100
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

NCT01050257
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir IV, Oseltamivir Oral
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

NCT02603952
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, MEDI8852, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Canoga Park, California • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 28, 2026, 9:38 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Oseltamivir in Newborns and Infants

NCT01388439
View directory record Official record
Conditions
Prematurity of Fetus
Interventions
Oseltamivir
Drug
Lead sponsor
St. Louis Children's Hospital
Other
Eligibility
Up to 6 Months
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 5, 2011 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

NCT01052480
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Anti-Influenza Immune Plasma, Standard Care
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
35
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

NCT01715909
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects

NCT01179919
View directory record Official record
Conditions
Obesity
Interventions
Oseltamivir
Drug
Lead sponsor
Manjunath Prakash Pai
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Paramaus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 28, 2026, 9:38 PM EDT
Recruiting Phase 2 Interventional

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

NCT04712539
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Influenza
Interventions
Baloxavir Marboxil, Oseltamivir
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers

NCT01172847
View directory record Official record
Conditions
Healthy Volunteer
Interventions
oseltamivir [Tamiflu], rimantadine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

NCT01258530
View directory record Official record
Conditions
Influenza, Human
Interventions
over-encapsulated oseltamivir, oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 2 Interventional

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

NCT00979251
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir Phosphate, ADS-8902
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine

NCT00416962
View directory record Official record
Conditions
Healthy
Interventions
amantadine hydrochloride, oseltamivir phosphate
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 4 Interventional Results available

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

NCT02609399
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Peramivir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies.

NCT00304434
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Probenecid
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2009 · Synced Sep 28, 2026, 9:38 PM EDT
Completed No phase listed Observational Results available

Influenza Resistance Information Study

NCT00884117
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
4,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A

NCT03040141
View directory record Official record
Conditions
Influenza A
Interventions
Low dose of VIS410, High dose of VIS410, Placebo
Drug
Lead sponsor
Visterra, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
21
States / cities
Tucson, Arizona • Stanford, California • St. Petersburg, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)

NCT01048879
View directory record Official record
Conditions
Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir
Interventions
pharmacokinetic blood sampling, pharmacokinetic blood and dialysate sampling
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 1 Interventional Results available

A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza

NCT01033734
View directory record Official record
Conditions
Influenza
Interventions
oseltamivir [Tamiflu]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year to 12 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
36
States / cities
Los Angeles, California • Oakland, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 4 Interventional Results available

A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants

NCT00412737
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 2 Interventional

Alternative Oseltamivir Dosing Strategies

NCT00334529
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 2Phase 3 Interventional

COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)

NCT04327791
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir, Placebos
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Springfield, Massachusetts • Cooperstown, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 28, 2026, 9:38 PM EDT
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

NCT02369159
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Oseltamivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
0 Days to 17 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Shreveport, Louisiana • Dayton, Ohio • Smithfield, Pennsylvania + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 28, 2026, 9:38 PM EDT